Dr. Satvinder Kaur is an Assistant Professor at Beth Israel Deaconess Medical Center in Boston, Massachusetts. She holds a PhD in Sleep Neurobiology from the University of Delhi. Her research focuses on the neural circuits regulating sleep, arousal, pain, and breathing, with particular expertise in respiratory control, brainstem circuitry, and sleep-related disorders. She has published extensively in leading scientific journals, including Nature Communications and Neuron.

Title: Interactive μ‑Opioid and α₂‑Adrenergic Signaling in the Parabrachial Area may mediate Fentanyl–Xylazine Co‑Administration Induced Sustained Suppression of Respiration and Hypothermia 

Abstract:

Background and Purpose:

It’s been reported that illicit drug supplies increasingly contain the α₂‑adrenergic agonist, xylazine, alongside fentanyl, yet the pharmacological basis for the greater lethality of this combination remains unclear.

Our lab has previously shown that the parabrachial (PB) glutamatergic populations—especially the FoxP2‑expressing neurons in the Kölliker‑Fuse (KF) and centro-lateral PB, have been shown to regulate ventilation, and drive cold‑defense pathways that maintain core temperature. These circuits, therefore, represent plausible sites on which fentanyl acts targeting the μ‑opioid (Oprm1) receptors, and α₂‑adrenergic (Adra2a) receptors, on which xylazine acts, as both are expressed within brainstem circuits that govern autonomic control and may regulate respiration. Thus, we propose that co‑activation of these inhibitory receptors and their respective pathways could potentiate or additively suppress respiratory and thermoregulatory function.

Experimental Approach:

Freely behaving C57BL/6J mice received intraperitoneal injections of either saline, fentanyl, xylazine, or fentanyl–xylazine (F+X) solutions. Continuous recordings of respiration using whole‑body plethysmography, sleep/wale state using EEG/EMG and body temperature using both infrared thermography, and telemetry were collected for several hours following injection. RNAscope was used to identify Oprm1 and Adra2a expression within PB and KF nuclei.

Results:

Fentanyl alone produced dose‑dependent respiratory depression that was not associated with body temperature (Tb) changes, whereas the dose we used of xylazine alone had no effect on either respiration or body temperature. In contrast, F+X induced a markedly prolonged (>5 h) reduction in respiratory rate and profound hypothermia lasting 7–8 h, exceeding the effects of either drug alone. Mortality increased to 58.8% following F+X exposure. RNAscope revealed that both Oprm1 and Adra2a receptors are expressed in PB/KF FoxP2‑positive neurons, identifying a plausible substrate for convergent inhibitory signaling.

Implications:

This manuscript provides the first direct experimental evidence that fentanyl and xylazine may interact through convergent μ‑opioid and α₂‑adrenergic receptor signaling to produce additive and sustained suppression of respiratory and thermoregulatory function. These findings address a critical mechanistic gap in understanding the disproportionate lethality of fentanyl–xylazine mixtures, an emerging public‑health crisis. The work further identifies the PB/KF FoxP2 population as a plausible site of dual‑receptor convergence and highlights a previously unrecognized pharmacodynamic interaction with immediate implications for overdose reversal strategies. Given the novelty, mechanistic insight, and translational urgency of these results, rapid dissemination will help accelerate scientific and clinical responses to this evolving threat.